Acid Reflux News Sept 29 2009

Survey reveals high awareness of acid reflux, but shows patients aren't doing enough to manage their 

(ARA) - At some point in their lives, almost everyone has heartburn -- that burning, uncomfortable feeling in the chest that often follows a big meal. For many people, heartburn only happens once in a while.

Lexington Clipper-Herald:

http://www.lexch.com/articles/2009/09/26/ara/senior_living/8588.txt

=====================================================

Eisai Submits Application for Additional Indication of its Proton Pump Inhibitor

PARIET(R) for Non-Eisai Co., Ltd. announced today that it had submitted an application for additional indication of its proton pump inhibitor PARIET(R) (generic name: rabeprazole sodium) for non-erosive gastro-esophageal reflux disease (GERD) in Japan.

ITNews:

http://www.itnews.it/news/2009/0929105201914/eisai-submits-application-for-additional-indication-of-its-proton-pump-inhibitor-pariet-r-for-non-erosive-gerd-in-japan.html

Free Press columnists predict today's Lions game

Mitch Albom -- Lions 23, Redskins 20 I don't know why, call it a hunch, a premonition, or acid

reflux. But I think they could (gulp) win.

Detroit Free Press: http://www.freep.com/article/20090927/SPORTS01/909270469/1048/rss03

=====================================================

Addex Completes Enrollment Of First Mid-Stage Clinical GERD Trial

Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, announced the completion of enrollment in the Phase IIb trial of ADX10059 as a monotherapy in patients with gastroesophageal reflux disease (GERD), the cause of heartburn and other symptoms.

Medical News Today:

 http://www.medicalnewstoday.com/articles/165416.php

=====================================================

Related Articles

Addex Pharmaceuticals has completed the enrollment in the phase IIb trial of ADX10059 as a monotherapy in patients with gastroesophageal reflux disease (GERD). ADX10059 is a first-in-class reflux inhibitor that works by reducing activation of the metabotropic glutamate receptor 5 (mGluR5) through negative allosteric modulation (NAM). ADX10059 also is in clinical trials to treat GERD patients who ...

Pharmaceutical Business Review:

http://www.pharmaceutical-business review.com/News/addex_completes_enrollment_for_first_midstage_clinical_gerd_trial_090928

=====================================================